SYNTHON HISPANIA SL
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Medicinal Chemicals and Botanical Products), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about SYNTHON HISPANIA SL
Live alerts from global media, monitored by Business Radar
2024-07-03 (cionoticias.tv)
New bioequivalent and biocomparable alternatives to cancer treatments are launched in Mexico
Synthon, a leading European pharmaceutical company in oncological and highly specialized bioequivalents and biocomparables, launches two new therapies to the Mexican market for
Read more
2024-06-21 (enfarma.lat)
Synthon launches new alternatives for bioequivalent and biocomparable treatments for cancer in Mexico
Release. Synthon, a European pharmaceutical company focused on oncological and highly specialized bioequivalents and biocomparables, announced that it launched two new cancer therapies to the Mexican market.
Read more
2023-11-14 (pharmabiz.net)
Synthon launched Osiren in Costa Salguero
Synthon-Bagó held an event to launch its new product Osiren MS. This is their brand indicated for multiple sclerosis and based on ozanimod. The main neurologists were summoned to the meeting held last Thursday in Costa Salguero.
Read more
2014-02-04 (vaktechnisch.nl)
Start new construction mAb Plant Synthon
Last week, pharmaceutical company Synthon gave the official go-ahead for the realization of a new factory on the Microweg in Nijmegen. In this so-called mAb plant, the company will produce therapeutic monoclonal antibodies.
Read more